Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 132 clinical trials
Featured trial
  • 29 Sep, 2022
  • 1 location
Clinical Trial To Evaluate Safety And Efficacy Of US-APR2020 In Subjects With Chronic Kidney Disease Stage IV (CKD)

The aim of this Phase 2 study is to evaluate the safety and efficacy of the live biotherapeutic product, US-APR2020, in the management of patients with CKD Stage IV.

  • 15 Jun, 2022
  • 5 locations
Twice Against Thrice-weekly Hemodialysis (TATH)

Hemodialysis is the most worldwide prescribed renal replacement therapy for patients with end-stage renal disease. The frequency of sessions per week remains a debatable issue. In the majority of developed Western and Asian countries, patients on chronic hemodialysis are undergoing three dialysis sessions weekly. In developing countries and some developed …

chronic renal failure
chronic hemodialysis
renal replacement therapy
  • 26 Feb, 2022
  • 1 location
TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients (INTERCEPT)

months. Protocol kidney graft biopsies will be performed at baseline, at 12 and 24 months. The primary outcome is the mean rate of change in graft function as assessed by estimated glomerular filtration

  • 22 Mar, 2022
Viral Load Guided Immunosuppression After Lung Transplantation (VIGILung)

(TTV viral load in whole blood) compared to conventional calcineurin inhibitor dosing. Indicator for toxicity will be the glomerular filtration rate (GFR), which will be estimated using the CKD-EPI

  • 10 Jul, 2022
  • 2 locations
Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection - A Phase 2 Pilot Trial

This prospective trial will assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and efficacy of the fully human CD38 monoclonal antibody felzartamab in kidney transplant recipients with late active or chronic-active ABMR. The study is designed as a randomized, controlled, double-blind pilot phase 2 trial. Participants will be randomized to receive …

  • 17 Sep, 2022
  • 1 location
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)

An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care

  • 25 Jul, 2022
  • 10 locations
CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

This is a Phase II/III, Single-center, Prospective, Open-label, Single Arm Study of 30 Simultaneous Kidney Pancreas recipients who received a transplant at least 3 months, but no more than 5 years prior, with a history of tremors following transplantation.

  • 21 Apr, 2022
  • 1 location
RandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis (REAL-LIFE)

Background: The thrice-weekly hemodialysis (HD) regimen is widely accepted as a standard prescription. The concept of incremental dialysis has been established as a possible alternative for patients with preserved diuresis and end-stage renal failure in need of HD. The main problems related to prescription of incremental HD are an arbitrary …

  • 04 Jun, 2022
  • 1 location
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts (PAES)

An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal disease (ESRD) patients with positive crossmatch (XM) against a deceased donor prior to desensitized with imlifidase and subsequent kidney transplantation. Two non-comparative reference cohorts are included to assess the impact of …

  • 11 Jul, 2022
  • 4 locations